Introduction
Antigen-specific TCR gene transfer enables the instantaneous ���������� �f ��f���� T ���� ���u���� ��� TCR ����-modified T cells are fully functional in vitro ��� �� �u���� models (1) (2) (3) (4) (5) (6) . The retroviral transfer of a MART1-specific TCR for adoptive T cell therapy first used in clinical trials on �������� �������� ������������ ��� f����b����� �f TCR ���� therapy (7, 8) . However, several factors currently limit the effi-���� ��� ������ ��� ����������� �f TCR ���� ���u���������. O�� �f ����� �������� ���u�� �� ���� ��� ������u��� TCRα ��� β ����� ��� ����������� �����b�� w��� ��������u� TCR ������ ��.�., TCR ���������� �, w���� ��� ���� ���u��� ��� �x����-���� �f ��� ������� TCR ����, bu� ��� ������ � ��w TCR w��� unknown specificity that can potentially cause autoimmunity ��� �ff-������ ��x����� �9,10�.
A �u�b�� �f ���������� ���� b��� ������������ �� ������� ��� ��x�� TCR ����� f��������. Ex������ �f �u�� ���������� ��� ��� ����������� �f ��� C ������� �f ��� TCRα ��� β ������ b� ��� ������������� �u���� ������� �11,12�, ������u����� �f an additional inter-chain disulfide bond between the constant ������� �f TCRα ��� β ������ �13,14�, ��� ��������� �f ����� ���� �����u�� �� ��� �������� ������ �f ��� TCRα ��� β ������ ���� f��� ��� TCR �����f��� �15�, ��� ��� u�� �f ������-����� TCR ���TCR� ��������, ����u���� �����-������ TCR� ���� ������� ����� ��������� �������, �u�� �� CD3ζ �� F�εRIγ �VαVβCβCD3ζ� �16-18�. H�w����, ��� fu�� �x���� �� w���� ����� ���������� ��� ������� TCR ����� ���������� �� u������.
I� � ������ ��u��, w� ���� �������� � TCR �Vα12 ��� Vβ7) from tumor infiltrating lymphocytes (TILs) of patients �HLA-A 2+ and AFP + � w��� ����������u��� ��������� �19�. W� ������������ ���� T ����� ������� f��� ������� ������ ����� ����f��� b� �u���-�����f�� TCR ���� �����f�� w��� ���� �ff������ ���� T ����� ������� f��� CD8 + T cells modified b� TCR ���� �����f�� �� ���u���� CTL �������� ��� �ff����� ����k��� ���������. H�w����, w���-���� �w��TCRα12 ��� β7 �x�������� �� ������u��� �u��� T ����� w�� ��w�� ���� ��� ������ �f ��������u� TCR ������, ���������� w��� ��� �����-���u� TCR. 
Imaging of T-cell receptor fused to CD3ζ reveals enhanced expression and improved pairing in living cells

Materials and methods
Cells, genes and reagents. Jurkat/E6-1 (ATCC TIB-152) cells were cultured in RPMI-1640 medium (Gibco/Invitrogen, Carlsbad, CA, USA), human embryonic kidney cells (HEK293) and human hepatocellular carcinoma cells (BEL-7402; maintained in our laboratory) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco/Invitrogen). All cultures were supplemented with 10% fetal bovine serum (FBS; Gibco/Invitrogen), 100 U/ml streptomycin and 100 U/ml peni-������. T�� TCRα12 ��� β7 ������ w��� �������� Fig. 2A . V����b�� f�������� f�� ���������� TCRαζ-ECFP (including TCRα, CD3ζ-a and EYFP) and TCRβζ-EYFP (including TCRβ, CD3ζ-b and ECFP) were amplified using a set of forward primers and reverse primers. The first step of SOE PCR reactions w�� ���f����� w��� 100 �� �3 f�������� w��� ��x�� w��� �� �qu������ ������ �f �������� w����u� �������, 10X Buffer, 2 mM dNTPs, 25 mM MgSO 4 , 0.5 U KOD-Plus-Neo Polymerase in a 25 µl reaction volume. The PCR cycling conditions were as follows: initial denaturation at 94˚C for 2 min, followed by 5 cycles at 94˚C for 30 sec, at 57˚C for 30 sec and at 68˚C for 1.5 min and completed with a final extension at 68˚C for 7 min. This initial PCRs generate overlapping gene segments that are then used as template DNA for the second step of SOE PCR to ������ � fu��-������ ����u��. T����f���, ������� 25 µ� �������� ��x�u�� ����������� 10X Buffer, 2 mM dNTPs, 25 mM MgSO 4 , 0.5 KOD-Plus-Neo Polymerase and 1 µM forward primer P1/ P1' and reverse primer P6/P6') was added to the first reaction mixture for the second step of SOE PCR. The reaction conditions were initial denaturation at 94˚C for 2 min, followed by 30 cycles at 94˚C for 30 sec, at 62˚C for 30 sec, and at 68˚C for 1.5 min and a final extension at 68˚C for 7 min, 2 µl of the ��������� w��� �����z�� b� ������� ��� ��������������� �1.0%� ( Fig. 2B and C) . Primer sequences for the amplification of �����b�� ������� ��� fu���� ������ ��� ��������� �� T�b�� I. T�� w�TCRα-ECFP and wtTCRβ-EYFP fusing sequences were ��������� u���� ��� ���� �������.
Vector construction. T� ������u�� � b���������� ������ �x�������� b��� ��� TCRαζ-ECFP and TCRβζ-EYFP chains, ��� fu���� ��qu����� TCRαζ-ECFP and TCRβζ-EYFP were cloned into the original pIRES2-EGFP vector (Clontech Laboratories, Inc., Palo Alto, CA, USA). The TCRαζ-ECFP fu���� ���� w�� �������� ���� ��� BstXI/NotI ����������� ���� of the pIRES2-EGFP vector (Clontech Laboratories), located ��w������� �f �� �������� ��b������ ����� ���� �IRES� sequence of the plasmid to replace the EGFP gene, then the TRBζ-EYFP fusion gene was inserted into the NheI/SalI ����������� ����, ������� u������� �f IRES. T�� ����� b����-tronic vector expressing both non-modified wtTCRα-ECFP ��� w�TCRβ-EYFP was constructed in a manner similar to ��� �b���-��������� ������u��. T�� ������ ������� �x�������� TCRα-ECFP or TCRβ-EYFP which were used to remove the spectral bleed-through (SBT) contamination in the FRET ������ w��� ������u���� �� ������u��� ������b�� �20�. T�� identity of all constructs was verified by direct sequencing. (21) which contained the Ad35 fiber knob ������������ ���� �� A�5 ������ �� ��� ���k����� ������, ��� ��� w���� w�TCRαβ �������� �TCRβ-IRES-TCRα� ��� TCRαζβζ �������� �TCRβζ-IRES-TCRαζ� w�� ������ ���� ��� ��u���� ������� ��DC315� �F��. 4A�. A��������� ��������� w��� produced by co-transfection of the packaging cells, HEK293, w��� A�5F35 ������ ��� �����b����� �DC315, ���������� w�TCRαβ �� TCRαζβζ. T�� ���u�-���������� �u���������� were filtered through 0.45-µm filters. Adenoviral particle titers w��� ��������� b� ��� 50% ����u� �u��u�� ��f�����u� ���� �TCID50� ������ ��� ��� �u���������� w��� �������� u��� f�� ��� ��f������ �f ��� ������ Ju�k�� T �����. F�� Ju�k�� T ���� ������u�����, 6-w��� ������ w��� ������ w��� Ju�k�� ����� �� 1x10 6 cells/well in 2 ml of RPMI 1640 medium supplemented with 2% FBS, cultured for 35 min, and then transduced with MOI 100 PFU of wtTCRαβ �� TCRαζβζ ����� �u����������. Following culture for 24 h at 37˚C with 5% CO 2 , ��� �u��u�� medium was replaced with RPMI 1640 medium supplemented with 10% FBS. After a further 48-h culture period, the cells were analyzed for TCR expression by flow cytometry.
Production of adenoviral particles and the transduction of TCR gene into Jurkat cells. W� u��� ��� A�5F35 �������� adenoviral vector
Flow cytometry. T�� TCR-������u��� Ju�k�� T ����� �5x10
5 � were analyzed for transgene expression by flow cytometry using FITC-conjugated anti-TCRVα12 mAb and PE-conjugated anti-TCRVβ7 �Ab�. T�� ����� w��� ���ub���� w��� ��� �Ab� �� ��� f�� 30 ���. Sub��qu�����, ��� Ju�k�� ����� w��� w����� �w��� with PBS and centrifuged for 10 min at 1000 x g, and the cell pellet was resuspended and fixed with 2% paraformaldehyde before taking measurements on an Epics XL flow cytometer (Beckman Coulter). The samples were analyzed using EXPO32 software (Beckman Coulter) and are displayed as dotplots.
Imaging by CLSM. T�� �����b����� �������, �IRES-TCRβ-EYFP/TCRα-ECFP and pIRES-TCRβζ-EYFP/TCRαζ-ECFP, were transfected into the Jurkat and BEL-7402 cells using Lipofectamine LTX/PLUS (Invitrogen) according to the ���uf���u���'� �����u������. T�� ����� �����f����� w��� �IRES-TCRα-ECFP and pIRES-TCRβ-EYFP were used as controls to remove the SBT contamination in FRET analysis. After 24 � �f �����f������, ��� Ju�k�� ����� ���w� �� �����-b����� dishes were washed twice with PBS and immobilized with 0.05% low metling agarose for 15 min and the BEL-7402 cells were washed twice with PBS solution. Confocal images �f ��� ����� w��� ��qu���� u���� �� O����u� F�u�V��w 1000 ���f���� ����� �������� ���������� w��� FV10-ASW 1.7 ��f�w��� �O����u�, T�k��, J�����. T�� FRET ����� �TCRα-ECFP or TCRαζ-ECFP) was excited with a 458 nm Ar-laser ��� ��� �������� �TCRβ-EYFP or TCRβζ-EYFP) was excited w��� � 515 �� A�-�����. T�� ����� w��� ������� f��� 475 �� 585 �� w��� � 10 �� ����-��z� ��� 20 �� b���-w���� �� �b���� �������� ������. was performed using two-way ANOVA with a Bonferroni's multiple comparisons test using Graphpad Prism 6 software (GraphPad Software Inc., San Diego, CA, USA). Differences with P-values <0.05 were considered statistically significant. D��� ��� �x������� �� ��� ����� ± SD.
Results
TCRαζβζ generation and location on the surface of cells.
We designed a modified TCR in which the extracellular and ��������b���� ������ �f TCRα �� β ������ w��� �x������� f�� CD3ζ ������ �� � ���u��u����� f�����b�� ��������. T� b����� observe the expression of the modified TCRαζβζ �� ������ �����, w� fu��� ��� C ������u� �f TCRαζ ��� TCRβζ ������ to a pair of cyan and yellow fluorescent proteins, ECFP and EYFP, respectively (Fig. 1) . The fusion genes, TCRαζ-ECFP ��� TCRβζ-EYFP, were obtained by SOE PCR (Fig. 2B ��� C�. T� ������� ��� �������� ������ �f �u�f��� �x�������� w��� w�TCRαβ, w� ���� fu��� ��� C ������u� �f ��� w�TCRα ��� w�TCRβ chains to a pair of ECFP and EYFP fluorescent �������� �F��. 1�. T�� fu���� ����� w��� ���� ������ ���� ��� pIRES2-EGFP vector. We first examined whether the TCRαζ-ECFP and TCRβζ-EYFP fusion chains are expressed on the surface of the cells. W� �����f����� ��� �����b����� �������� ���� Ju�k�� �����, �� well as BEL-7402 cells, and 24 h after transfection, the fluo-�������� �b��������� b� CLSM �������� ���� ��� ������u��� fu���� �����, TCRαζ-ECFP and TCRβζ-EYFP, were located �� ��� ������ ���b���� �f ��� ����� ��� w��� �ff�������� �x������� �� T ����� ��� ���-T ����� �F��. 3�. (Fig. 5B) . The average FRET efficiency between wtTCRα ��� β chains (10.5±1.0%) was significantly reduced compared �� ��� TCRαζ ��� βζ chains (17.1±2.1%) in BEL-7402 cells (P<0.0001) (Fig. 5D) . The results indicated that the assemble �f w�TCRα ��� β ������ w�� �������� �� ��� �b����� �f CD3 subunits, in spite of no endogenous TCR in the BEL-7402 �����. Of ����, w� f�u�� ���� ��� ������� FRET �ff������� b��w��� TCRαζ-ECFP and TCRβζ-EYFP in the BEL-7402 ����� �17.1±2.1%� w�� ��� ���u��� �������� �� ��� Ju�k�� ����� (16.7±2.5%) (P>0.05) (Fig. 5D) . These results demonstrated ���� ��� �x�������� ��� �����b�� �f TCRαζβζ w�� ��� ������-����� ���� w����u� ��� CD3γε, δε ��� ζζ ��������� ������ �� the BEL-7402 cells.
TCRαζβζ enhanced surface expression in T cells and non-T cells. W� �b������ � ���� ����������� ����������
Discussion
In the present study, we generated several ECFP and EYFP fu����� �� � ���� �f ��������� ���� ����w ��� ���������� �f ��� �x�������� ��� ������� b��w��� TCRαζ ��� TCRβζ �� ������ �����. F����, w� u��� � w�TCRαβ �Vα12 ��� Vβ7� �������� f��� TIL� �f �������� fu��� �� �������� �u��� CD3ζ �����u�� �� �������� � ���� �f �������� TCRαζ ��� TCRβζ, then ECFP fu��� �� TCRαζ, and EYFP fused to TCRβζ via overlap PCR, In conclusion, using the strategy of fluorescent proteins fu��� �� ��� TCRαζ ��� βζ ������ w� ��������� ��� ����u��� ��� �x�������� ��� ����������� �f TCRαζ ��� TCRβζ �� living cells accurately. The ECFP and EYFP fusion reporters �������� ���� ��� TCRαβ ������ fu��� �� CD3ζ �������� ��� �x�������� ��� ��������� ����������, ������ ��� w�� �� �����-���� ���u��������� ��u���� ������� w��� TCR ����������.
